HOME ·

03174.HK

Expectations Realized! Hong Kong Healthcare Sustains Recovery, CSOP Hang Seng Biotech ETF (03174.HK) Surges Over 3.5% Intraday
Tags：
NewTimeSpace03174.HK
2026-02-10
Hong Kong stock market innovation drug-related targets collectively weakened, with CSOP Hang Seng Biotech ETF (03174.HK) falling over 2.5%, despite continued growth in innovative drug BD transactions.
Tags：
NewTimeSpace03174.HK
2026-01-30
The Hong Kong stock market is once again swinging lower, with healthcare shares leading the decline; CSOP Hang Seng Biotech ETF (03174.HK) has dropped more than 2.3%.
Tags：
NewTimeSpace03174.HK
2026-01-26
Hong Kong pharma names have pulled back for several consecutive sessions; CSOP Hang Seng Biotech ETF (03174.HK) slipped 1.2%. The innovation theme is expected to stay on the radar in 2026.
Tags：
NewTimeSpace03174.HK
2026-01-22
HK healthcare names hit hard — WuXi Biologics leads the slide; CSOP Hang Seng Biotech ETF (03174.HK) sinks nearly 3%.
Tags：
NewTimeSpace03174.HKCSOP Hang Seng Biotech ETF
2026-01-19
JPM Conference kicks off—CSOP Hang Seng Biotech ETF (03174.HK) and Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) both surge over 3%.
Tags：
03174.HK03069.HKNewTimeSpace
2026-01-13
CSOP Hang Seng Biotech ETF (03174.HK) has shown strong performance at the start of the year, with a cumulative increase of over 10%! Its gain ranks among the top in the Hong Kong stock ETF market today.
Tags：
CSOP Hang Seng Biotech ETF03174.HKCSOP Asset Management
2026-01-07